Page 3 - Repligen Daily News Today

Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen […]

Repligen (NASDAQ:RGEN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen also updated […]

Repligen (NASDAQ:RGEN – Free Report) had its target price lifted by KeyCorp from $210.00 to $220.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other research reports. JPMorgan Chase & Co. upped their price target on […]

Headlands Technologies LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 474 shares of the biotechnology company’s stock, valued at approximately $75,000. Several other institutional investors have also recently added to […]

Headlands Technologies LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 474 shares of the biotechnology company’s stock, valued at approximately $75,000. Several other institutional investors have also recently added to […]

Alliance Wealth Advisors LLC UT lifted its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 9.8% in the third quarter, HoldingsChannel.com reports. The fund owned 2,346 shares of the biotechnology company’s stock after acquiring an additional 210 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Repligen were worth $373,000 […]

Victory Capital Management Inc. boosted its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 27.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,420 shares of the biotechnology company’s stock after buying an additional 4,228 […]

Daiwa Securities Group Inc. lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 3.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,200 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the period. Daiwa […]

Repligen (NASDAQ:RGEN – Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a breakdown of current ratings […]

Westfield Capital Management Co. LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 20.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 294,222 shares of the biotechnology company’s stock after purchasing an additional 49,727 shares during the quarter. Westfield Capital […]